Daiichi Sankyo : Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer(204.8KB

Press Release Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer • Application based on results from the TROPION-Breast01 phase 3 trial • Additional BLA under review in the U.S. for Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan for [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.